Secure payment on i-micronews Contact Yole Développement for I Micronews reports

RSS I-micronewsYole Dévelopement on TwitterYole Développement on Google +LinkedIn Yole pageSlideshare Yole Développement I-Micronews

MedTech

Guardant Health said that it is working with Bristol-Myers Squibb to develop the GuardantOMNI assay, a 500-plus-gene liquid biopsy panel designed to accelerate clinical trials and targeted cancer therapy research.

Read more ...

Systems, reagents, and software to cover broad range of clinical applications. Illumina announced today the introduction of its NextSeq 550Dx instrument, the company’s second FDA-regulated and CE-IVD marked next-generation sequencing (NGS) system. The company also announced that the intended use for the MiSeqDx instrument has been updated to include the use of DNA libraries generated from formalin-fixed paraffin embedded (FFPE) tissues, paving the way for clinical labs to use FFPE samples when developing clinical tests for new applications.

Read more ...

ABILIFY MYCITE® (aripiprazole tablets with sensor) is a drug-device combination product comprised of Otsuka’s oral aripiprazole tablets embedded with an Ingestible Event Marker (IEM) sensor. The ABILIFY MYCITE® System includes: ABILIFY MYCITE®, the MYCITE® Patch (wearable sensor); the MYCITE® APP (a smartphone application); and web-based portals for healthcare providers and caregivers

Read more ...

Clearbridge BioMedics and Leica Biosystems have announced a partnership, co-marketing each other's products to support circulating tumor cell (CTC) research. This is specifically for the Clearbridge BioMedics ClearCell® FX CTC enrichment system and the Leica Biosystems' BOND RX staining platform.

Read more ...

Created by medical practitioners and the world’s foremost experts at the cutting edge of imaging technology, this two-day conference in central London addresses the need for an integrated approach to developing medical imaging systems for clinical use.

Read more ...

Nexstim, a medical technology company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic and diagnostic applications, announces that the Food and Drug Administration (“FDA”) has cleared Nexstim’s NBT® system for marketing and commercial distribution in the US for the treatment of Major Depressive Disorder (MDD).

Read more ...

Upcoming Events


> Biological and Chemical Sensors Summit 2017
(December 5 - December 7, San Diego, USA)